Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
暂无分享,去创建一个
Karla Perez-Toralla | Valérie Taly | Pierre Laurent-Puig | Ouriel Caen | P. Laurent-Puig | H. Blons | V. Taly | Ouriel Caen | Audrey Didelot | Hélène Blons | Fanny Garlan | Nicolas Pécuchet | A. Didelot | F. Garlan | Elizabeth Fabre | Eleonora Zonta | Coren Milbury | C. Milbury | E. Fabre | N. Pécuchet | E. Zonta | K. Perez-Toralla
[1] Meizhuo Zhang,et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance , 2016, Scientific Reports.
[2] P. Laurent-Puig,et al. [Digital PCR compartmentalization I. Single-molecule detection of rare mutations]. , 2015, Medecine sciences : M/S.
[3] K. Kinzler,et al. Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[4] Yang Zhang,et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations , 2016, OncoTargets and therapy.
[5] M. Duffy,et al. p53 as a target for the treatment of cancer. , 2014, Cancer treatment reviews.
[6] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[7] P. Laurent-Puig,et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. , 2012, Experimental and molecular pathology.
[8] P. Nizard,et al. Assessment of DNA Integrity, Applications for Cancer Research. , 2015, Advances in clinical chemistry.
[9] S. Laufer,et al. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[10] Yong He,et al. Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma. , 2015, The Journal of molecular diagnostics : JMD.
[11] A. Lièvre,et al. Cetuximab Therapy in Colorectal Cancer Mutation Status Is Predictive of Response to KRAS Updated , 2006 .
[12] H. Bai,et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer , 2016, Oncotarget.
[13] D. Link,et al. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations , 2014, Biomolecular detection and quantification.
[14] Qun Zhong,et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. , 2011, Lab on a chip.
[15] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Klaus Pantel,et al. Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.
[17] P. Laurent-Puig,et al. PCR digitale en micro-compartiments - I. Détection sensible de séquences d’acides nucléiques rares , 2015 .
[18] Bruno Landi,et al. Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.
[19] Yate-Ching Yuan,et al. Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy , 2014, Human mutation.
[20] Allison Hills,et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.
[21] S H Neoh,et al. Quantitation of targets for PCR by use of limiting dilution. , 1992, BioTechniques.
[22] T. Mok,et al. Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.
[23] R. McCormack,et al. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] Tania Nolan,et al. The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. , 2013, Clinical chemistry.
[25] J. Pagès,et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Masahiko Ando,et al. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR , 2015, Clinical Cancer Research.
[27] I. Wistuba,et al. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. , 2013, Lung cancer.
[28] S. Morita,et al. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. , 2015, Lung cancer.
[29] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[30] Peter Ulz,et al. Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.
[31] Ye Zhang,et al. The impact of R213 mutation on p53-mediated p21 activity. , 2014, Biochimie.
[32] J. Kere,et al. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. , 2015, Clinical Chemistry.
[33] A. Shaw,et al. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Valérie Taly,et al. Detecting biomarkers with microdroplet technology. , 2012, Trends in molecular medicine.
[35] Alexander Dobrovic,et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations , 2015, Scientific Reports.
[36] S. Stein,et al. Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.
[37] P. Laurent-Puig,et al. PCR digitale en micro-compartiments - II. Apport pour la détection quantitative d’ADN tumoral circulant , 2015 .
[38] P. Laurent-Puig,et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.